In orphan drug development, smaller patient populations present unique challenges when it comes to demonstrating safety and efficacy to support regulatory approval. Similarly, 505(b)(2) drug development by definition utilizes publicly available data sources to support approval. 

In this webinar, we'll share insights to harness the strategic value of real world data to build optimized drug development programs that minimize the time and cost of sponsor-driven studies.

Featured Speaker

Kenneth V. Phelps

President & Founder

Ken Phelps is co-founder and president of Camargo. He has over 40 years of industry experience, including a number of executive-level positions in areas such as quality control, project management and regulatory, clinical and medical affairs.


Register now for this webinar